Spanish study checks if support programs help lung fibrosis patients on nintedanib
NCT ID NCT06912659
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This study follows 157 adults in Spain who have pulmonary fibrosis and are taking the medicine nintedanib while enrolled in a patient support program called Balance. Researchers want to see how satisfied patients are with the program and track their quality of life, mood, and any side effects over 12 months. The goal is to understand if the support program helps patients manage their treatment and well-being.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Evidenze Health Espana S.L.
Barcelona, 08005, Spain
Conditions
Explore the condition pages connected to this study.